A study of MK-2870 for several gastrointestinal cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal, pancreatic, or bile duct cancer that cannot be removed by surgery.
- If you've had cancer treatment before, you must have recovered from any side effects from that treatment.
- You must not have had any cancer therapy (including other experimental drugs) within the last 4 weeks before starting the study.
- You must not have a history of severe eye disease.
- You must not have had or currently have a lung condition called interstitial lung disease or pneumonitis (lung inflammation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new investigational drug (MK-2010) combined with sacituzumab tirumotecan (Sac-TMT) for people with various solid tumors. The goal is to see if the combination is safe and effective.
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
This trial tests a new drug (MK-1084) combined with other treatments for people with a specific type of advanced lung cancer (non-small cell, non-squamous) that has a KRAS G12C mutation. It is for those whose cancer has worsened after prior immunotherapy and chemotherapy.
This trial tests a new drug, MK-4716, alone or with cetuximab or pembrolizumab, for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.